Artelo Biosciences, Inc., a clinical-stage pharmaceutical company dedicated to modulating lipid-signaling pathways for developing treatments targeting cancer, pain, and neurological conditions, has chosen Worldwide Clinical Trials, a global contract research organization (CRO) specializing in neuroscience, oncology, rare diseases, and cardiometabolic and inflammatory disease, to assist in the planned Phase 1 trial of ART26.12. This compound is Artelo's Fatty Acid Binding Protein 5 (FABP5) inhibitor designed for addressing chemotherapy-induced peripheral neuropathy (CIPN).
With the global neuropathic pain market valued at an estimated $7.6 billion, there is a significant demand for innovative therapies offering relief to patients experiencing pain and with limited treatment options. Artelo has conducted five pre-clinical studies targeting painful neuropathies, including diabetic neuropathy and chemotherapy-induced peripheral neuropathy, the latter of which lacks FDA-approved treatments. The company has previously reported a positive pre-IND (investigational new drug) meeting with the FDA and expects to file the IND for ART26.12 in the first half of the current year.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!